Medicine and Dentistry
Placebo
100%
Rituximab
92%
Allograft Vasculopathy
35%
Combination Therapy
28%
Cardiac Allograft Vasculopathy
21%
Atheroma
21%
Heart Transplantation
21%
B Cell
21%
Intravascular Ultrasound
14%
Mortality
14%
Antibody
7%
Follow up
7%
Cell Population
7%
Depletion
7%
Transplantation
7%
Coronary Artery
7%
Heart Graft
7%
CD20
7%
Acute Graft Rejection
7%
Development
7%
Organ Transplantation
7%
Posttransplant Lymphoproliferative Disease
7%
HLA Antibody
7%
Differentiation
7%
Donor
7%
Immunology and Microbiology
Rituximab
92%
Transplantation
42%
B Cell
21%
Volume
21%
CD19
14%
Mortality
14%
Monospecific Antibody
7%
Cell Population
7%
Lymphoproliferative Disorders
7%
Coronary Artery
7%
Acute Graft Rejection
7%
CD20
7%
HLA Antibody
7%
Development
7%
Differentiation
7%
Heart
7%
Organ Transplantation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
92%
Clinical Trial
42%
Atheroma
21%
Cardiac Allograft Vasculopathy
21%
Mortality
14%
Antibody
7%
Acute Graft Rejection
7%
Posttransplant Lymphoproliferative Disease
7%
HLA Antibody
7%
Neuroscience
Rituximab
92%
Placebo
50%
B Cell
21%
Intravascular Ultrasound
14%
CD19
14%
Antibodies
7%
CD20
7%
HLA Antibody
7%
Biochemistry, Genetics and Molecular Biology
Rituximab
85%
B Cell
21%
Volume
21%
CD19
14%
Mortality
14%
Development
7%
CD20
7%